DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2217329/idexx-laboratories-idxx-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217329 Jan 29, 2024 - Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4. 0

https://www.zacks.com/stock/news/2222832/exelixis-exel-q4-earnings-beat-on-lower-r-d-spend-sales-miss?cid=CS-ZC-FT-analyst_blog|earnings_article-2222832 Feb 07, 2024 - Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates. 0

https://www.zacks.com/stock/news/2224881/what-s-in-the-cards-for-medtronic-mdt-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2224881 Feb 12, 2024 - Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance. 0

https://www.zacks.com/stock/news/2227756/can-rigel-pharmaceuticals-rigl-beat-q4-earnings-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227756 Feb 19, 2024 - Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth. 0

https://www.zacks.com/stock/news/2228601/sarepta-therapeutics-srpt-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2228601 Feb 20, 2024 - Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2233462/sarepta-therapeutics-srpt-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233462 Feb 28, 2024 - The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2234137/sarepta-srpt-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2234137 Feb 29, 2024 - Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys. 0

https://www.fool.com/investing/2024/03/13/does-this-1-new-threat-make-sarepta-therapeutics/?source=iedfolrf0000001 Mar 13, 2024 - The threat is still emerging, but it could be significant. 0

https://www.zacks.com/stock/news/2227400/henry-schein-hsic-set-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227400 Feb 16, 2024 - Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges. 0

https://www.zacks.com/stock/news/2227548/corcept-cort-q4-earnings-beat-estimates-korlym-sales-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2227548 Feb 16, 2024 - Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024. 0